Agios Pharmaceuticals, Inc.AGIONASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 81% recommend buying.

Consensus Rating

Buy

27 analysts·High coverage

81%

Rating Distribution

Strong Buy

00%

Buy

2281%

Hold

519%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 48% higher.

Bear Case

$25.00

-10%

Consensus

$41.25

+48%

Bull Case

$62.00

+122%

Price Range27 analysts

Low

Consensus

High

$25.00

$62.00

Current Target

Current Price

$27.93

Upside to Target

$13.32

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-6.59(9 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+129.94%

EPS—

FY2028

Rev+108.82%

EPS—

FY2029

Rev+60.58%

EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+8.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 26, 2025Leerink Partners

Agios Pharmaceuticals price target raised to $40 from $34 at Leerink

Target:$40.00

+37.1%from $29.17

Dec 24, 2025H.C. Wainwright

Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright

Target:$62.00

+112.5%from $29.17

Dec 24, 2025Truist Financial

Agios Pharmaceuticals price target raised to $38 from $32 at Truist

Target:$38.00

+30.3%from $29.17

Nov 24, 2025Truist Financial

Agios Pharmaceuticals initiated with a Buy at Truist

Target:$32.00

+26.8%from $25.24

Nov 20, 2025Goldman Sachs

Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs

Target:$25.00

-2.2%from $25.55

Nov 20, 2025Leerink Partners

Leerink upgrades Agios to Outperform after 51% pullback

Target:$34.00

+52.2%from $22.34

Oct 20, 2025H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Target:$56.00

+32.3%from $42.33

May 2, 2025Scotiabank

Agios Pharmaceuticals price target lowered to $71 from $74 at Scotiabank

Target:$71.00

+135.9%from $30.10

Oct 31, 2024Raymond James

Raymond James Reiterates Outperform Rating on Agios Pharma (AGIO)

Target:$51.00

+14.8%from $44.43

Sep 27, 2024Leerink Partners

Leerink Partners Downgrades Agios Pharma (AGIO) to Market Perform

Target:$56.00

+22.8%from $45.61

Sep 10, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Target:$56.00

+27.1%from $44.05

Jun 17, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Target:$55.00

+26.7%from $43.42

Jun 3, 2024RBC Capital

Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital

Target:$53.00

+19.7%from $44.26

May 28, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Target:$45.00

+17.2%from $38.39

Feb 3, 2023Piper Sandler

Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41

Target:$41.00

+35.9%from $30.18

Dec 1, 2022J.P. Morgan

JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $33

Target:$33.00

+12.0%from $29.46

Nov 17, 2022Goldman Sachs

Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32

Target:$32.00

+18.0%from $27.13

Apr 30, 2021Barclays

Agios Pharmaceuticals price target raised to $70 from $65 at Barclays

Target:$70.00

+25.4%from $55.80

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance